Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXO1 | Q12778 | 11/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22489142 | 0.89 | FOXO1 (0.80) | FOXO1SMN1; SMN2PDE10APDPK1ACHE | |
| SCHEMBL22489139 | 0.87 | FOXO1 (0.77) | FOXO1PDE10APDPK1ACHE | |
| SCHEMBL22489135 | 0.87 | FOXO1 (0.77) | FOXO1SMN1; SMN2PDE10APDPK1ACHE | |
| SCHEMBL22489136 | 0.85 | FOXO1 (0.74) | FOXO1NPC1RAB9ASMN1; SMN2PDE10A | |
| SCHEMBL22489166 | 0.81 | FOXO1 (0.69) | FOXO1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL24512908 | 0.79 | FOXO1 (0.80) | FOXO1NPC1RAB9APDE10AACHE | |
| SCHEMBL30754034 | 0.78 | FOXO1 (0.64) | FOXO1PDE10AACHE | |
| SCHEMBL25429204 | 0.78 | FOXO1 (0.64) | FOXO1PDE10AACHE | |
| SCHEMBL4919646 | 0.78 | FOXO1 (0.64) | FOXO1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL1646084 | 0.77 | FOXO1 (0.62) | FOXO1NPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185797-A1 | SELECTIVE FOXO INHIBITORS FOR TREATMENT OF DIABETES AND OTHER DISORDERS RELATED TO IMPAIRED PANCREATIC FUNCTION | FOXO1, FOXO3, FOXK1 | FOXO1 1/4885NPC1 3743/4885RAB9A 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.